|
|
|
| home > white papers > High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts - ILC Dover |
|
|
 WHITE PAPERS |
|
ILC Dover
|
|
High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts
|
|
As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Elsevier launches solution to accelerate drug discovery through comprehensive prediction and assessment of drug-drug interactions
More info >> |
|
 |
White Papers |
 |
|
Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments
World Courier
It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >> |
|
 |
Industry Events |
 |
7th annual Orphan Drugs and Rare Diseases UK
18-19 October 2017, Holiday Inn Kensington Forum, London
SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >> |
|
|
|
